PT378 – Course Corrections, Preparation, and High-dose Experiences: “Who Are You...

Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises...

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health...

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort...

First Patient Dosed in Small Pharma’s Drug Interaction Study

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Revive Therapeutics Ltd. Expands Life Offering to Quebec

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani,...

Psychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics,...

Load more